2. Academic Validation
  3. Oncogenic signaling of MEK5-ERK5

Oncogenic signaling of MEK5-ERK5

  • Cancer Lett. 2017 Apr 28:392:51-59. doi: 10.1016/j.canlet.2017.01.034.
Van T Hoang 1,  Thomas J Yan 1,  Jane E Cavanaugh 2,  Patrick T Flaherty 2,  Barbara S Beckman 3,  Matthew E Burow 4
Affiliations

Affiliations

  • 1 Department of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
  • 2 Department of Pharmacological Sciences, Division of Medicinal Chemistry, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
  • 3 Department of Pharmacology, Tulane University, New Orleans, LA, USA.
  • 4 Department of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA; Department of Pharmacology, Tulane University, New Orleans, LA, USA; Tulane Cancer Center, Tulane University, New Orleans, LA, USA. Electronic address: [email protected].
PMID: 28153789 DOI: 10.1016/j.canlet.2017.01.034
Abstract

Mitogen-activated protein kinases (MAPKs) regulate diverse cellular processes including proliferation, cell survival, differentiation, and Apoptosis. While conventional MAPK constituents have well-defined roles in oncogenesis, the MEK5 pathway has only recently emerged in Cancer research. In this review, we consider the MEK5 signaling cascade, focusing specifically on its involvement in drug resistance and regulation of aggressive Cancer phenotypes. Moreover, we explore the role of MEK5/ERK5 in tumorigenesis and metastatic progression, discussing the discrepancies in preclinical studies and assessing its viability as a therapeutic target for anti-cancer agents.

Keywords

Cellular signaling; Kinase inhibitors; MEK5-ERK5; Mitogen-activated protein kinase; Targeted therapies.

Figures